Delayed Danish state Covid vaccine to be trialled on humans in 2022

National Danish infectious disease research organization Statens Serum Institut has found a manufacturer for its in-house Covid-19 vaccine, moving it closer to testing the candidate on human subjects following a series of delays.

Seruminstituttets chefvirolog Anders Fomsgaard siger, at man er tæt på | Photo: Tobias Nicolai/IND

Denmark's second coronavirus vaccine, Covaxix, which is being developed by National Danish infectious disease research organization Statens Serum Insitut (SSI), has come closer to being tested on humans in phase I and II trials in 2022 after a string of delays.

A manufacturer has now been found in the US through a solicitation process, says SSI Chief Virologist Anders Fomsgaard.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs